DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.message sent
email sent successfully
rareLife solutions 606 Post Road East #397 Westport, CT 06880 |
||
You are receiving this because you have an account on www.oneSMAvoice.com | ||
If you'd like to unsubscribe and stop receiving these emails click here |
Trusted Resources: News & Meetings
Latest announcements and gatherings
FDA Grants Evrysdi® Priority Review Based on Results From Treating Pre-Symptomatic Infants With Spinal Muscular Atrophy
PTC Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted priority review of a supplemental new drug application (sNDA) for Evrysdi® (risdiplam) to expand the indication to include pre-symptomatic infants under 2 months old with spinal muscular atrophy (SMA). If approved, Evrysdi would be the first medicine administered at-home for pre-symptomatic babies with SMA.
The results demonstrating that almost all of the pre-symptomatic infants achieved motor milestones comparable to healthy infants is tremendous,” said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics. “The granting of the Priority Review for Evrysdi recognizes this and the significant need to treat babies with SMA as early as possible. We are proud that such a transformative treatment for patients living with SMA came from our splicing platform.
Related Content
-
Community CenterAn Experimental Gene Therapy Was Little Alissa’s Only HopeThomas Feldborg and Daria Rokina set off...
-
News & MeetingsWill Parental Vaccine Hesitancy Retard the Embrace of Life-Saving Newborn Genetic Screening and Emerging Gene Therap...In these days of the never-ending pandem...
-
People & PlacesCHOP – Spinal Muscular Atrophy (SMA)Why Choose CHOP for SMA Treatment?Being ...
-
News & MeetingsA ‘Miracle’: Spinraza Gives Boy, Now 5, a Chance to Grow UpIt’s now been more than four years sin...
-
EducationNatural History of Spinal Muscular Atrophy in Children: An Analysis of 117 CasesObjectives: To study the natural history...
-
Community CentermySMAteam – FacebookmySMAteam is the social network for thos...
-
EducationFilling the Gaps in Knowledge Translation: Physical Therapy Recommendations for Individuals With Spinal Muscular Atr...This study describes the current landsca...
send a message
Reset password
password changed successfully!
please log in with your email address and new password.
your activation key expired
this confirmation key has expired. please try to log in again or resend confirmation email.
confirmation email sent
a confirmation email has been sent to your inbox. click the link in the email to activate your account.
can't find the email? be sure to check your spam folder.
password reset email sent
an email has been sent to you with a link to reset your password.
can't find the email? be sure to check your spam folder.
If you are a doctor or other qualified health care professional, you should not offer any medical advice or treatment on our Sites, nor should you allow the content of our Sites to substitute for your own medical judgment. Please thoroughly review the information provided on our Sites before deciding whether any of the products, services, or treatments therein are right for you or others.
your account is now activated!
Log in
This feature is only available to members.
you haven't confirmed your email address yet. resend confirmation email